Effect of dosing frequency on chronic cardiovascular disease medication adherence

References

• Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US), 2004. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension [Last accessed 8 November 2011]
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al.; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32
   PubMed Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814-22
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Kalaian HA, Raudenbush SW. A multivariate mixed linear model for meta-analysis. Psychological Methods 1996;13:227-35
   Web of Science ®Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research Website. ISPOR medication compliance and persistence special interest group (MCP). Available at: http://www.ispor.org/sigs/mcp_accomplishments.asp [Last accessed 8 November 2011]
   Google Scholar
• Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-52
   PubMed Web of Science ®Google Scholar
• Doró P, Benkő R, Czakó A, et al. Optimal recall period in assessing the adherence to antihypertensive therapy: a pilot study. Int J Clin Pharm 2011;33:690-5
   PubMed Web of Science ®Google Scholar
• Kronish IM, Rieckmann N, Shimbo D, et al. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol 2010;15;106:1090-4
   Web of Science ®Google Scholar
• Platt AB, Localio AR, Brensinger CM, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 2010;137:883-9
   PubMed Web of Science ®Google Scholar
• Stilley CS, Bender CM, Dunbar-Jacob J, et al. The impact of cognitive function on medication management: three studies. Health Psychol 2010;29:50-5
   PubMed Web of Science ®Google Scholar
• Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. J Card Fail 2009;15:385-93
   PubMed Web of Science ®Google Scholar
• Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag 2007;3:235-42
   PubMedGoogle Scholar
• Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al.; Compliance Group of the Spanish Society of Hypertension (SEE). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens 2006;24:169-75
   PubMed Web of Science ®Google Scholar
• Tu W, Morris AB, Li J, et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 2005;77:189-201
   PubMed Web of Science ®Google Scholar
• Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents. J Hypertens 2004;22:1409-14
   PubMed Web of Science ®Google Scholar
• Kardas P. COMPASS Investigators. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol 2004;15;94:213-16
   Web of Science ®Google Scholar
• Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219-28
   PubMedGoogle Scholar
• Laporte S, Quenet S, Buchmüller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003;89:458-67
   PubMed Web of Science ®Google Scholar
• Bohachick P, Burke LE, Sereika S, et al. Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs 2002;17:160-6
   PubMedGoogle Scholar
• Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998;16:1049-54
   PubMed Web of Science ®Google Scholar
• Schwed A, Fallab CL, Burnier M, et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999;39:402-9
   PubMed Web of Science ®Google Scholar
• Waeber B, Leonetti G, Kolloch R, et al. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999;17:1041-5
   PubMed Web of Science ®Google Scholar
• Waeber B, Vetter W, Darioli R, et al. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 1999;53:37-8
   PubMed Web of Science ®Google Scholar
• Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13:914-20
   PubMed Web of Science ®Google Scholar
• Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials 1997;18:187-203
   PubMedGoogle Scholar
• Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996;14:137-44
   PubMed Web of Science ®Google Scholar
• Mason B. Anticoagulant clinic warfarin adherence rates and assessment. J Pharm Technol 1996;12:97-101
   Google Scholar
• Straka RJ, Fish JT, Benson SR, et al. Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease. J Clin Pharmacol 1996;36:587-94
   PubMed Web of Science ®Google Scholar
• Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994;22:266-72
   PubMed Web of Science ®Google Scholar
• Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994;32:452-7
   PubMed Web of Science ®Google Scholar
• Kruse W, Nikolaus T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993;45:211-15
   PubMed Web of Science ®Google Scholar
• Rudd P, Ramesh J, Bryant-Kosling C, et al. Gaps in cardiovascular medication taking: the tip of the iceberg. J Gen Intern Med 1993;8:659-66
   PubMed Web of Science ®Google Scholar
• Rudd P, Ahmed S, Zachary V, et al. Compliance with medication timing: implications from medication trial for drug development and clinical practice. J Clin Res Pharmacoepidemiol 1992;6:15-27
   Google Scholar
• Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4
   PubMed Web of Science ®Google Scholar
• Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987;2:298-305
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-36
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
   PubMed Web of Science ®Google Scholar
• Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org [Last accessed 17 September 2011]
   Google Scholar